Gilead Sciences, together with Mylan Laboratories, Ranbaxy Laboratories and Strides Arcolab, have entered into a collaboration to promote access to generic versions of Gilead’s HIV medicine emtricitabine (FTC) in developing countries, including single tablet regimens and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines. Gilead will provide technology transfer for the manufacture of emtricitabine, as well as funding for process improvements to reduce overall ...